Belgium's UCB to buy Ra Pharmaceuticals for $2.1 billion

UCB has agreed to acquire U.S.-based Ra Pharmaceuticals for $2.1 billion, in a deal that will enable the Belgian drugmaker to offer new treatment opportunities for several rare diseases in neurology and immunology.

from Reuters: Health News https://ift.tt/326SEzC